|


Associated
Vision Consultants Now Offers New Treatment Which Promises Help
for Many Patients With Macular Degeneration
A
procedure called Ophthalmic Photodynamic Therapy was recently approved
by the Food and Drug Administration. It promises to help many people
who are in the early stages of wet macular degeneration.
Wet macular degeneration results when abnormal blood
vessels develop in the eye and leak fluid or blood, blurring central
vision. There is also dry macular generation caused
by the aging and thinning of the tissues of the macula. Both types
are age-related, found mostly in those over age 60. The best candidates
for the new photodynamic therapy are those in the early stages of
wet macular degeneration. Patients are evaluated with
an office procedure called fluorescein angiography to determine
if treatment is possible
The new system,
Visudyne , now in use at Associated Vision Consultants, consists
of an intravenous dye injection followed by a specific type of laser
treatment. The dye (Verteporfin) is infused into the patients
arm for exactly 10 minutes, then after a wait of 5 minutes, a red
(689 nm) diode laser is used to activate the dye, which has accumulated
in the area of macular degeneration. This causes the abnormal vessels
to close and disappear leaving no damage to the retina. Lasers used
in the past coagulated the leaking vessels but also left a scar
on the retina. The new procedure allows greater accuracy that ever
before and eliminates scarring. The procedure is done in the office
and takes about 45 minutes. After the procedure patients are advised
that the dye sensitizes the entire body to light, and that they
must stay out of sunlight for 5 days following the procedure. Some
patients may require 3 or 4 treatments approximately 3 months apart
for the procedure to be successful. This new procedure is the most
exciting advance in treatment of macular degeneration since the
first laser became available in the late 1960s .
If you have macular degeneration please contact
us to find out if you are a candidate for this new treatment.
|